BioPharmSignal logoBioPharmSignal

Biotech News

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. (ATRA)Atara Biotherapeutics, Inc.FDA / regulatory

ATRA (ATRA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is atra.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

ATRAAtara Biotherapeutics, Inc.2026-08-12 20:05 EST

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

REPLReplimune Group2026-06-26 12:00 EST

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

REGNRegeneron Pharmaceuticals2026-06-22 11:00 EST

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

GSKGSK plc2026-08-24 07:01 EST

Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer

RVMDRevolution Medicines2026-07-22 20:05 EST

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

INBXInhibrx2026-06-15 13:15 EST

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

REGNRegeneron Pharmaceuticals2026-08-19 17:58 EST

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

View all latest news

Atara Biotherapeutics, Inc.

Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Its platform does not require T-cell-receptor or HLA gene editing. Tabelecleucel Tabelecleucel, also known as tab-cel or EBVALLO, is an allogeneic EBV-specific T-cell...

Recent company news

ATRAAtara Biotherapeutics, Inc.2026-08-12 20:05 EST

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

ATRAAtara Biotherapeutics, Inc.2026-06-12 20:00 EST

Atara Biotherapeutics Announces Changes to Its Board of Directors

ATRAAtara Biotherapeutics, Inc.2026-05-12 20:05 EST

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

ATRAAtara Biotherapeutics, Inc.2026-05-07 12:05 EST

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

ATRAAtara Biotherapeutics, Inc.2026-03-16 20:05 EST

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Stock data

Close
9.70 USD
Market cap
89.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States